Virax Biolabs Group

VRAXNasdaq United Kingdom Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$2.375 M

$2.98 +7.58%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

579,218

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#15VolitionrxVNRX$9.34M
#16Trinity BiotechTRIB$8.39M
#17Cardio DiagnosticsCDIO$5.30M
#18BiomericaBMRA$4.98M
#19Virax Biolabs GroupVRAX$2.38M

Where these numbers come from

Share counts and financials for Virax Biolabs Group are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.